SOURCE: PharmaCom BioVet, Inc.

October 15, 2008 08:41 ET

PharmaCom BioVet, Inc. Introduces Novel Cancer Treatments in Partnership With IsoTherapeutics Group

RALEIGH, NC--(Marketwire - October 15, 2008) - PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce they have entered into a collaborative agreement with IsoTherapeutics Group (ITG) to co-develop and introduce novel therapeutic treatments for companion animals.

With a special interest in radiopharmaceuticals for oncology, ITG focuses on the development of technologies aiding in the diagnosis and treatment of debilitating diseases such as cancer.

"PharmaCom BioVet's relationship with IsoTherapeutics Group will enable significant development in the research of a variety of therapeutic treatments geared towards lymphoma and other forms of companion animal cancers," said Gary Berthold, Founder, President/CEO of PharmaCom BioVet, Inc. "Through these efforts, PharmaCom BioVet will be poised to introduce novel treatment procedures throughout our cancer centers and the veterinary community."

"ITG is developing novel technologies for the therapeutic treatment of cancers," said R. Keith Frank, Ph.D., Co-Founder and President/CEO of IsoTherapeutics Group, LLC. "Through our relationship with PharmaCom BioVet we are excited that we will be able to introduce these new treatments into the veterinary marketplace."

PharmaCom BioVet, Inc. seeks to further the opportunities available to people who have encountered cancer in their companion animals and to offer their animals a better quality of life and longevity. In response to demand and the current lack of adequate cancer treatment options and facilities for animal lovers whose pets are suffering from cancer, PharmaCom BioVet intends to open a network of companion animal cancer care centers throughout North America.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the Veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website www.PharmaComBioVet.com.

About IsoTherapeutics Group, LLC:

The mission of IsoTherapeutics Group, LLC is to develop novel diagnostic and therapeutic agents for the treatment of severe diseases. ITG develops both proprietary technologies as well as partners with other companies to help develop pharmaceuticals. Of special interest are radiopharmaceuticals for oncology. In house expertise includes synthetic organic chemistry, chelation chemistry, radiochemistry, diagnostic and therapeutic isotopes, conjugation chemistry, pharmacokinetics, and small animal research models. For more information, please visit our website www.isotherapeutics.com.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact Information